Abstract:AIDS Research and Human RetrovirusesVol. 30, No. S1 Novel Vaccine ConceptsFree AccessLive Adenovirus Type 4 Recombinants Induce Durable Neutralizing Antibody Responses to Influenza H5 with High Levels of Somatic Hypermutation in HumansJinghe Huang, Byong Kang, Adam Wheatley, Sandeep Narpala, Adrian Mcdermott, April Poole, Robert Bailer, Richard Koup, Stephen Migueles, Marc Gurwith, and Mark ConnorsJinghe HuangNIAID/LIR, HIV-Specific Immunity Section, Bethesda, MD, United StatesSearch for more papers by this author, Byong KangNIAID/LIR, HIV-Specific Immunity Section, Bethesda, MD, United StatesSearch for more papers by this author, Adam WheatleyNIAID, NIH, Vaccine Research Center, Bethesda, MD, United StatesSearch for more papers by this author, Sandeep NarpalaNIAID, NIH, Vaccine Research Center, Bethesda, MD, United StatesSearch for more papers by this author, Adrian McdermottNIAID, NIH, Vaccine Research Center, Bethesda, MD, United StatesSearch for more papers by this author, April PooleNIAID/LIR, HIV-Specific Immunity Section, Bethesda, MD, United StatesSearch for more papers by this author, Robert BailerNIAID, NIH, Vaccine Research Center, Bethesda, MD, United StatesSearch for more papers by this author, Richard KoupNIAID, NIH, Vaccine Research Center, Bethesda, MD, United StatesSearch for more papers by this author, Stephen MiguelesNIAID/LIR, HIV-Specific Immunity Section, Bethesda, MD, United StatesSearch for more papers by this author, Marc GurwithPaxVax Inc., La Jolla, CA, United StatesSearch for more papers by this author, and Mark ConnorsNIAID/LIR, HIV-Specific Immunity Section, Bethesda, MD, United StatesSearch for more papers by this authorPublished Online:30 Oct 2014https://doi.org/10.1089/aid.2014.5073.abstractAboutSectionsPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail OA16.01Background: Induction of durable antibody responses capable of neutralizing diverse HIV-1 isolates is the most important goal in HIV vaccinology. Broad and potent HIV Env-specific antibodies isolated from humans are characterized by binding to conserved sites on Env and by high levels of hypermutation. Live virus recombinant vectors may provide prolonged exposure to transgene-encoded antigen and may more potently drive affinity maturation than non-replicating vectors. We report results of a small Phase 1 trial of mucosal immunization with live adenovirus type 4 encoding influenza H5 HA (Ad4-H5-Vtn) as a model antigen. We explored its ability to induce durable, broad neutralizing antibody responses through upper respiratory tract application.Methods: Live Ad4-H5Vtn (103-108 viral particles (VP)) was administered by tonsillar swab or by nasal spray in a dose escalation study. Controls received (1010 VP) as enteric-coated capsules. Neutralizing antibodies were measured by a pseudotype HA lentiviral vector system. B cells were isolated using fluorescent HA probes. Immunoglobulin genes were cloned for mutation analysis, and re-expressed to measure neutralization potency and breadth.Results: The vaccine was well tolerated and symptoms were consistent with mild URI. Tonsillar and nasal immunizations were the most immunogenic routes inducing neutralizing antibody responses at day 60 (ID50=809 and 666 respectively) which rose during the first 6 months. B cells that expanded early were specific for both H1 and H5 and were directed to the conserved stalk, with H5 HA-monospecific cells expanding by 6 months. The median level of hypermutation was 3.6% compared to germline at week 4 and 7.4% at weeks 34–52. However, some antibodies contained 13–34% mutation and neutralized group 1 and 2 viruses.Conclusions: A single dose of live recombinant Ad4-H5 can induce highly mutated antibodies, suggesting that mucosal administration is a promising platform for the induction of HIV-specific neutralizing antibodies.FiguresReferencesRelatedDetails Volume 30Issue S1Oct 2014 InformationCopyright 2014, Mary Ann Liebert, Inc.To cite this article:Jinghe Huang, Byong Kang, Adam Wheatley, Sandeep Narpala, Adrian Mcdermott, April Poole, Robert Bailer, Richard Koup, Stephen Migueles, Marc Gurwith, and Mark Connors.Live Adenovirus Type 4 Recombinants Induce Durable Neutralizing Antibody Responses to Influenza H5 with High Levels of Somatic Hypermutation in Humans.AIDS Research and Human Retroviruses.Oct 2014.A44-A44.http://doi.org/10.1089/aid.2014.5073.abstractPublished in Volume: 30 Issue S1: October 30, 2014PDF download

High-Throughput Screening for the Prevalence of Neutralizing Antibodies against Human Adenovirus Serotype 5

[Monocytes Are More Susceptible in Vitro in Rhesus Macaques of Chinese Origin to Recombinant Serotype 5 Adenovirus with Higher Preexisting Vector Specific Neutralizing Antibody Titer].

A Novel Polyclonal Antibody Against Human Cytomegalovirus: General Characteristics and Potential Application in Diagnosis

Neutralizing monoclonal antibodies protect against human adenovirus type 55 infection in transgenic mice and tree shrews

Isolation of novel simian adenoviruses from macaques for development of a vector for human gene therapy and vaccines

Identification of Broadly Applicable Adeno-Associated Virus Vectors by Systematic Comparison of Commonly Used Capsid Variants In Vitro

Analysis of the Prevalence of Binding and Neutralizing Antibodies against 39 Human Adenovirus Types in Student Cohorts Reveals Low-Prevalence Types and a Decline in Binding Antibody Levels during the SARS-CoV-2 Pandemic

Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity

Novel Surrogate Neutralizing Assay Supports Parvovirus B19 Vaccine Development for Children with Sickle Cell Disease

RSV A2-Based Prefusion F Vaccine Candidates Induce RSV A and RSV B Cross Binding and Neutralizing Antibodies and Provide Protection against RSV A and RSV B Challenge in Preclinical Models

Preparation and Identification of Monoclonal Antibodies Against the Adenovirus Vector

Induction of neutralizing antibody responses by AAV5-based vaccine for respiratory syncytial virus in mice

Development of a High-Throughput Respiratory Syncytial Virus Fluorescent Focus-Based Microneutralization Assay.

Virus neutralization assays for human respiratory syncytial virus using airway organoids

High-Throughput In Vitro, Ex Vivo, and In Vivo Screen of Adeno-Associated Virus Vectors Based on Physical and Functional Transduction

Circumventing Antivector Immunity by Using Adenovirus-Infected Blood Cells for Repeated Application of Adenovirus-Vectored Vaccines: Proof of Concept in Rhesus Macaques

Neutralizing Antibody Evasion Ability Of Adenovirus Vector Induced By The Bioconjugation Of Methoxypolyethylene Glycol Succinimidyl Propionate (Mpeg-Spa)

Live Adenovirus Type 4 Recombinants Induce Durable Neutralizing Antibody Responses to Influenza H5 with High Levels of Somatic Hypermutation in Humans

Recombinant influenza virus carrying human adenovirus epitopes elicits protective immunity in mice

Development of monoclonal antibodies targeting the conserved fragment of hexon protein to detect different serotypes of human adenovirus

Prediction of adeno-associated virus neutralizing antibody activity for clinical application